四川精神卫生
四川精神衛生
사천정신위생
SICHUAN MENTAL HEALTH
2015年
3期
215-218
,共4页
陈景旭%梁雪梅%卞清涛%刘可智%张立刚%张荣珍%李伟%刘艳红
陳景旭%樑雪梅%卞清濤%劉可智%張立剛%張榮珍%李偉%劉豔紅
진경욱%량설매%변청도%류가지%장립강%장영진%리위%류염홍
利培酮%高催乳素血症%精神分裂症%阿立哌唑
利培酮%高催乳素血癥%精神分裂癥%阿立哌唑
리배동%고최유소혈증%정신분렬증%아립고서
Risperidone%Hyperprolactinemia%Schizophrenia%Aripiprazole
目的探讨阿立哌唑治疗利培酮所致高催乳素血症的效果是否存在性别差异。方法采用分层随机方法将116例利培酮所致高催乳素血症的精神分裂症患者分为研究组(男性28例,女性31例)和对照组(男性26例,女性31例)。维持原有利培酮治疗方案不变,研究组合并用阿立哌唑20mg·d-1,对照组合并安慰剂治疗。于基线期、治疗第2、4、8周末检测血清催乳素水平,于基线期、治疗8周末采用UKU副作用评定量表( UKU)评定药物不良反应。结果在治疗后第2、4、8周末,研究组男性、女性分别与对照组男性、女性血清催乳素水平比较差异均有统计学意义( P均﹤0.01)。研究组男性、女性在治疗后第2、4、8周末血清催乳素水平分别与其基线期比较,差异均有统计学意义(P﹤0.01),而在第2周、第4周、第8周末同组内两两比较,差异无统计学意义(P﹥0.05)。对照组男性、女性血清催乳素水平治疗前后差异无统计学意义( P﹥0.05)。8周末,研究组男性、女性催乳素水平下降率[(79.61±17.81)%vs.(75.54±12.96)%]差异无统计学意义( P﹥0.05),研究组男性高催乳素血症治愈率(92.9%)高于女性(58.1%)(χ2=9.39,P﹤0.001)。结论合并阿立哌唑对利培酮所致的高催乳素血症在治疗第2周显效。在相同剂量下,对男性患者的疗效可能优于女性。
目的探討阿立哌唑治療利培酮所緻高催乳素血癥的效果是否存在性彆差異。方法採用分層隨機方法將116例利培酮所緻高催乳素血癥的精神分裂癥患者分為研究組(男性28例,女性31例)和對照組(男性26例,女性31例)。維持原有利培酮治療方案不變,研究組閤併用阿立哌唑20mg·d-1,對照組閤併安慰劑治療。于基線期、治療第2、4、8週末檢測血清催乳素水平,于基線期、治療8週末採用UKU副作用評定量錶( UKU)評定藥物不良反應。結果在治療後第2、4、8週末,研究組男性、女性分彆與對照組男性、女性血清催乳素水平比較差異均有統計學意義( P均﹤0.01)。研究組男性、女性在治療後第2、4、8週末血清催乳素水平分彆與其基線期比較,差異均有統計學意義(P﹤0.01),而在第2週、第4週、第8週末同組內兩兩比較,差異無統計學意義(P﹥0.05)。對照組男性、女性血清催乳素水平治療前後差異無統計學意義( P﹥0.05)。8週末,研究組男性、女性催乳素水平下降率[(79.61±17.81)%vs.(75.54±12.96)%]差異無統計學意義( P﹥0.05),研究組男性高催乳素血癥治愈率(92.9%)高于女性(58.1%)(χ2=9.39,P﹤0.001)。結論閤併阿立哌唑對利培酮所緻的高催乳素血癥在治療第2週顯效。在相同劑量下,對男性患者的療效可能優于女性。
목적탐토아립고서치료리배동소치고최유소혈증적효과시부존재성별차이。방법채용분층수궤방법장116례리배동소치고최유소혈증적정신분렬증환자분위연구조(남성28례,녀성31례)화대조조(남성26례,녀성31례)。유지원유리배동치료방안불변,연구조합병용아립고서20mg·d-1,대조조합병안위제치료。우기선기、치료제2、4、8주말검측혈청최유소수평,우기선기、치료8주말채용UKU부작용평정량표( UKU)평정약물불량반응。결과재치료후제2、4、8주말,연구조남성、녀성분별여대조조남성、녀성혈청최유소수평비교차이균유통계학의의( P균﹤0.01)。연구조남성、녀성재치료후제2、4、8주말혈청최유소수평분별여기기선기비교,차이균유통계학의의(P﹤0.01),이재제2주、제4주、제8주말동조내량량비교,차이무통계학의의(P﹥0.05)。대조조남성、녀성혈청최유소수평치료전후차이무통계학의의( P﹥0.05)。8주말,연구조남성、녀성최유소수평하강솔[(79.61±17.81)%vs.(75.54±12.96)%]차이무통계학의의( P﹥0.05),연구조남성고최유소혈증치유솔(92.9%)고우녀성(58.1%)(χ2=9.39,P﹤0.001)。결론합병아립고서대리배동소치적고최유소혈증재치료제2주현효。재상동제량하,대남성환자적료효가능우우녀성。
Objective To compare the efficacy and safety of adjunctive treatment with aripiprazole on hyperprolactinemia induced ky risperidone ketween different gender. Methods By using a stratified randomization protocol,116 schizophrenic patients with risperi=done- induced hyperprolactinemia were assigned to research group(28 male and 31 female)and control group(26 male and 31 female), and received 20mg·d-1 aripiprazole or placeko for adjunctive treatment respectively. Serum prolactin levels was measured at kaseline, the end of the 2nd,4th and 8th weed and UKU Side Effects Rating Scale(UKU)were assessed at kaseline and the end of 8th weed. Re-sults Compared with the kaseline,koth male and female in research group showed statistical difference in serum prolactin at the end of the 2nd,4th and 8th weed(P﹤0.001),kut here were no significant difference ketween the 2nd,4th and 8th weed in research group ketween and after treatment in control group(P﹥0. 05). At the end of the 8th weed,there was no statistical deference ketween male and female in research group in the decline rate of serum prolactin levels[(79. 61 ± 17. 81)%(,75. 54 ± 12. 96)%],and the normal ratio of male pa=tients were significantly higher(92. 9%)than that of female patients in research group(58. 1%)(χ2 =9. 39,P﹤0. 001). Conclusion Adjunctive aripiprazole treatment may ke effective for treating risperidone -induced hyperprolactinemia and achieved almost all of its effects after the 2nd weed. The effects on male patients was ketter than female patients with the same e dosage of aripiprazole.